Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab*

Carolina Forte Amarante1 Livia Mendes Sabia Acedo1 Fátima Maria de Oliveira Rabay1 Márcia Lanzoni de Alvarenga Lira1 Benedito do Espírito Santo Campos1 Samuel Henrique Mandelbaum1

Abstract: TNF alpha antagonist-induced lupus-like syndrome is a rare condition which predominantly affects women (4:1). The average age of onset is 46-51 years. It occurs after exposure to TNF alpha antagonist and disappears after discontinuation of such agents. The pathogenic mechanism for development of the TNF alpha antagonist-induced lupus-like syndrome is not fully defined. It is believed that the medication induces apoptosis, leading to an accumulation of nucleosomal antigens of apoptotic cells. This would cause autoantibodies to be produced by susceptible individuals. The most common cutaneous manifestations include maculopapular exanthem, malar rash, alopecia, photosensitivity and, more rarely, vasculitis. Extracutaneous manifestations include: fever, weight loss, arthritis or arthralgia, myositis and hematological abnormalities. Antinuclear antibody may be positive in 80% of cases and anti-histone antibody is considered a disease marker for TNF alpha antagonist-induced lupus-like syndrome. Treatment corresponds to drug discontinuation. We report a rare case of sub-acute cutaneous lupus erythematosus with leukocytoclastic vasculitis induced by adalimumab in a 42-year-old patient.

Keywords: Exposure to biological agents; Tumor necrosis factor-alpha; Vasculitis, leukocytoclastic, cutaneous

INTRODUCTION

Tumor necrosis factor (TNF) alpha is a pro-inflammatory cytokine that is implicated in the pathogenesis of many chronic inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriatic arthritis.1,2 TNF alpha antagonists were developed over a decade ago and have shown increasing success in controlling these diseases.3 One of the most common side-effects is the development of autoantibodies. Although the development of different autoantibodies is a common finding, only a few cases of drug-induced lupus erythematosus have been reported and they are rarely related to adalimumab.4,5,6 We report a rare case of Sub-acute cutaneous lupus erythematosus with leukocytoclastic vasculitis induced by adalimumab in a 42-year-old patient.
discrete purpuric papules on the ends of the fingers and periungual telangiectasias. There were no other systemic signs. Laboratory evaluation showed elevated ESR, positive ANA at a titer of 1: 640 with homogeneous pattern and positive anti-histone antibodies (Figures 1, 2 and 3).

Histopathology of an erythematous-violaceous papule on the skin of the right hand dorsum showed a predominantly neutrophilic inflammatory infiltrate in the interstitium and in the wall of the superficial and deep capillaries. There was fibrinoid change in the wall of these capillaries and leukocytoclasia, consistent with leukocytoclastic vasculitis (Figures 4 and 5).

Based on the clinical and histopathological findings, we made the diagnosis of drug-induced subacute cutaneous lupus erythematosus. Adalimumab was discontinued and cyclosporine (300 mg daily) was prescribed, with no improvement. After three months with no response, we introduced etanercept (50 mg weekly), with gradual reduction of cyclosporine. The patient had complete resolution of the symptoms, with no recurrence of psoriasis or lupus.

**DISCUSSION**

Drug-induced lupus-like syndrome (DILS) or, more specifically, TNF alpha antagonist-induced lupus-like syndrome is a rare condition which predominantly affects women (4:1). The average age of onset is 46-51 years. It occurs after exposure to TNF alpha antagonist and disappears after discontinuation of such agents.1

The time to onset of lupus symptoms after initiation of TNF alpha inhibitors ranges from 10 days to 54 months.1 Infliximab and etanercept are the most common agents but adalimumab, more rarely, can also trigger the disease.2-4 Adalimumab is the first fully human recombinant monoclonal IgG1 antibody which specifically binds to tumor necrosis factor alpha and neutralizes its biologic activity.2,4

The pathogenic mechanism for development of the TNF alpha antagonist-induced lupus-like syn-

---

**FIGURE 1:** Psoriatic plaque on the third metacarpophalangeal joint, erythematous-violaceous papules on the right hand dorsum

**FIGURE 2:** Purpuric papules on the distal ends of the right hand fingers

**FIGURE 3:** Erythematous-violaceous papule on the proximal interphalangeal joint of the left second finger

**FIGURE 4:** Predominantly neutrophilic inflammatory infiltrate in the interstitium and in the wall of the superficial and deep capillaries
drome is not fully defined. Some authors suggest that adalimumab, similarly to ultraviolet radiation in the pathogenesis of idiopathic lupus erythematosus, induces apoptosis, leading to an accumulation of nucleosomal antigens of apoptotic cells. This would cause autoantibodies to be produced by susceptible individuals. It was also suggested that the therapeutic inhibition of TNF-alpha would increase autoimmunity by inhibiting cytotoxic T lymphocytes.2

The drug-induced lupus-like syndrome can be subdivided into three clinical variants, namely: Drug-induced systemic lupus erythematosus (SLE), drug-induced sub-acute cutaneous lupus erythematosus and drug-induced chronic cutaneous lupus erythematosus. Clinical and laboratory characteristics of each of the aforementioned variants are shared by idiopathic lupus erythematosus.1

Systemic manifestations are: fever, weight loss, arthritis or arthralgia, myositis with elevated muscle enzymes, serositis and hematological disorders (ane-

mia, leucopenia and thrombocytopenia). The most common cutaneous manifestations include maculopapular rash, malar rash, alopecia and photosensitiv-
ity.1,4,5 The most common presentation of vasculitis is the development of cutaneous lesions characterized by purpura, especially in distal limb, face and ears, and periungual telangiectasias. Histological analysis of the skin lesions usually shows cutaneous leukocytoclastic vasculitis, a pattern found in hypersensitivity vasculitis, involving superficial and deep dermal ves-
sels, often with fibrin thrombi occluding vessels and associated frank necrosis.5

The least rigorous criteria for diagnosis requires one or more symptoms compatible with lupus erythematosus, ongoing exposure to a drug known to cause DILS, no prior history of lupus erythematosus, and resolution of symptoms when the offending drug is discontinued.1 There are no specific laboratory tests to diagnose DILS. Patients are screened for laborato-
ry abnormalities found in idiopathic SLE. Serological tests include: autoantibodies, blood profile and renal function.1-3 ANA can be positive in 80% cases and the anti-histone antibody is considered a disease marker. However, it is less common in DILS (17-57%).1

Treatment consists of drug discontinuation. Symptoms improve within 3 weeks to 6 months. Oral or injectable steroids, hydroxychloroquine or even immuno-
suppressive therapy such as azathioprine, cyclosporin, leflunomide, and methotrexate may be intro-
duced in some cases.1-3,7

The complete resolution of symptoms after dis-
continuation of the drug, after a careful clinical and laboratory research, which excluded other etiologies, together with the histological pattern found, strength-
en the diagnosis of drug-induced lupus erythemato-
sus syndrome with leukocytoclastic vasculitis associ-
ated with the use of adalimumab. Given the potential severity of these reactions, early diagnosis and the choice of alternative treatment methods for a favor-
able disease outcome are of paramount importance.
REFERENCES
1. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011;50:619-25.
2. Vezzoli P, Valdetti SA, Sarno MM, Munaron S, Bertol E, Crosti C. Cutaneous lupus erythematosus induced by adalimumab. J Dermatol. 2011;38:283-4.
3. Al-Amiri F. Adalimumab-induced lupus erythematosus. Eur J Dermatol. 2000;10:380.
4. Fionna S, Dembska S, Parente B, Allee M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-a agents. Autoimmun Rev. 2013;13:15-9.
5. Perez-Alvarez R, Perez-de-Luca M, Ramos-Casals M. BIOGEAS study group. Biological-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:54-44.
6. Cheow AL, Bennett A, Smith DH, Butler J, Kileham B. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol. 2004;151:490-6.
7. Esposito SA, Vitali PV, Mantovani FE, Zucca A, Drossa AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2006;35:228-31.
8. Martin JM, Reisert JA, Lillicr J, Russell N, Asano G. Adalimumab-induced lupus erythematosus. Lupus. 2008;17:676-8.
9. Criado PR, Criado RFJ. Reações adversas a drogas: o espectro dermatológico na prática clínica. Barueri: Editora Manole LTDA; 2014. p. 430-6.

How to cite this article: Amarante CF, Acedo LMS, Rabay FM O, Campos BES, Alvarenga Lira ML, Mandelbaum SH. Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab. An Bras Dermatol. 2015;90 (3 Suppl 1):S121-4.